Liquidia Corporation Common Stock (LQDA)

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also p…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

216

Website

www.liquidia.com

Fundamentals

1-day range

$71.53$76.87

Market cap

$7.46B

P/E (trailing)

53.17

P/E (forward)

13.18

EPS (trailing)

$1.40

Dividend yield

—

Beta

0.57

Avg. volume

1.93M

Forecasts

8 analyst ratings

Liquidia Corporation Common Stock Competitors

Chosen by industry and closest market cap.

• LQDA

  Liquidia Corporation Common Stock

  $67.69

  ▼ 3.22%
  Market cap $7.46BP/E 53.17
  $21.15$93.61
• COGT

  Cogent Biosciences Inc. Common Stock

  $34.68

  ▼ 6.50%
  Market cap $6.64BP/E —
  $11.6$43.73
• SYRE

  Spyre Therapeutics Inc. Common Stock

  $90.4

  ▼ 3.43%
  Market cap $8.35BP/E —
  $14.51$110.18
• MIRM

  Mirum Pharmaceuticals Inc. Common Stock

  $97.44

  ▼ 2.32%
  Market cap $6.38BP/E —
  $63.23$130
• ERAS

  Erasca Inc. Common Stock

  $18.03

  ▼ 7.49%
  Market cap $6.11BP/E —
  $1.33$24.28
• BLTE

  Belite Bio Inc American Depositary Shares

  $151.65

  ▼ 3.42%
  Market cap $6.09BP/E —
  $62.18$200
• LGND

  Ligand Pharmaceuticals Incorporated Common Stock

  $280

  ▼ 1.59%
  Market cap $5.85BP/E 38.07
  $158.4$326.63

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

66.53M

Total value held

$2.45B

Institutional holders

243